Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran

Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 83

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MISJ-8-1_001

تاریخ نمایه سازی: 25 آبان 1402

Abstract:

Background: Metastatic prostate cancer is one of the most important cancers among men worldwide. Androgen ablation therapy can be used in treatment of these patients; however, most will progress to metastatic hormone-refractory prostate cancer. In this regard, docetaxel has been approved to treat metastatic hormone-refractory prostate cancer in the United States. In this study, we aimed to investigate the results of this treatment modality in metastatic prostate cancer patients from Iran.Methods:We evaluated PSA response and bone pain relief in ۱۸ metastatic prostate cancer patients who underwent treatment with docetaxel at a dose of ۷۵ mg/m۲ intravenously on the first day of treatment. The treatment was repeated every three weeks (۶ cycles) along with ۱۰ mg of prednisolone.Results: Of ۱۸ patients, ۳۹% had >۵۰% decline in PSA levels.There were ۱۶% of the patients with a PSA decline of approximately ۳۰% to ۵۰% of the pre-treatment levels. In addition, ۲۹% of the patients had progressive PSA levels during chemotherapy. Among them, ۵۵% had significant pain relief.Conclusion: This research showed the effectiveness of docetaxel to decrease PSA levels in metastatic hormone-refractory prostate cancer patients from Iran. Docetaxel was also valuable in alleviation of pain in these patients. However, prospective studies should validate this approach.

Authors

Mina Tajvidi

Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Mahnaz Roayaei

Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Simin Hematti

Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Hadi Faezi

Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran